

Stock code: 300003      Stock abbreviation: Lepu Medical

Announcement No.: 2020-167

**Lepu Medical Technology (Beijing) Co., Ltd.**  
**Reminding Announcement on the SARS-CoV-2 Antigen Rapid Test Kit**  
**(Colloidal Gold Immunochromatography) was Shortlisted in Export "White**  
**List"**

**The company and all members of the Board of Directors hereby guarantee that the information presented in this Announcement is true, accurate and complete with no false or misleading statement or material omission. The English version of this Announcement is for reference only.**

The subsidiary company Beijing Lepu Medical Technology Co., Ltd. (hereinafter brief as "Lepu Diagnostics") of Lepu Medical Technology (Beijing) Co., Ltd. (hereinafter brief as "Lepu Medical") is always devoted to the research and development and manufacturing of products in the IVD field. The announcement is given that the Lepu Diagnostics self-developed SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography) was shortlisted in export "White List" recently. This is a new product getting the EU market access qualification again after independently developed SARS-CoV-2 Antibody Test (colloidal gold immunochromatography) got the EU market access qualification in March 2020.

The SARS-CoV-2 Antigen Rapid Test Kit, which is different with the antibody test kit, is intended for the qualitative detection of antigen against SARS-CoV-2 in clinical samples (nasal swab). The test card is based on the specific antibody-antigen reaction and immunoanalysis technology. The test card contains colloidal gold labeled SARS-CoV-2 N protein monoclonal antibody which is pre-coated on the combination pad, matched SARS-CoV-2 N protein monoclonal antibody immobilized on the Test area (T) and corresponding antibody in the quality control area (C) to realize more

rapid and accurate test. The clinical performance characteristics of the test kit has been evaluated in a clinical study in the Islamabad Diagnostic Center, Pakistan, with a diagnostic sensitivity of 97.47% and a diagnostic specificity of 95%.

The listing of the test kit in export "white list" will provide faster, more accurate and convenient on-site detection methods for the global COVID-19 suspected patients, patients who requires isolation or medical observation, and other people who require COVID-19 diagnoses. Lepu Diagnostics will increase productivity, actively ensure the safety and effectiveness of products, and prepare for the fight against the COVID-19, and make contribution to human health.

**The Board of Directors**

**Lepu Medical Technology (Beijing) Co., Ltd.**

**November 10, 2020**